Several Houston institutions scored funding from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

The Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants. Photo via Rice.edu

2 Houston health innovation leaders award grants to cancer-fighting researchers

dream team

Five cancer-fighting research projects were named inaugural recipients of a new grant program founded by two Houston institutions.

Last summer, Rice University and The University of Texas MD Anderson Cancer Center announced they were teaming up to form the new Cancer Bioengineering Collaborative. The shared initiative, created to form innovative technologies and bioengineering approaches to improve cancer research, diagnosis and treatment, recently launched with an event at the TMC3 Collaborative Building in Helix Park.

At the gathering, the Cancer Bioengineering Collaborative announced the projects that were selected for its first round of seed grants.

  • “Enhancing CAR-T immunotherapy via precision CRISPR/Cas-based epigenome engineering of high value therapeutic gene targets,” led by Isaac Hilton, associate professor of biosciences and bioengineering at Rice and a Cancer Research and Prevention Institute of Texas (CPRIT) scholar; and Michael Green, associate professor of lymphoma/myeloma at MD Anderson.
  • “Nanocluster and KRAS inhibitor-based combination therapy for pancreatic ductal adenocarcinoma,” led by Linlin Zhang, assistant research professor of bioengineering at Rice; and Haoqiang Ying, associate professor of molecular and cellular oncology at MD Anderson.
  • “Engineering tumor-infiltrating fusobacteriumas a microbial cancer therapy,” led by Jeffrey Tabor, professor of bioengineering at Rice; and Christopher Johnston, associate professor of genomic medicine and director of microbial genomics within the Platform for Innovative Microbiome and Translational Research at MD Anderson.
  • “Preclinical study of nanoscale TRAIL liposomes as a neoadjuvant therapy for colorectal cancer liver metastasis,” led by Michael King, the E.D. Butcher Professor of Bioengineering at Rice, CPRIT scholar and special adviser to the provost on life science collaborations with the Texas Medical Center; and Xiling Shen, professor of gastrointestinal medical oncology at MD Anderson.
  • “Deciphering molecular mechanisms of cellular plasticity in MDS progression,” led by Ankit Patel, assistant professor of electrical and computer engineering at Rice and of neuroscience at Baylor College of Medicine; and Pavan Bachireddy, assistant professor of hematopoietic biology and malignancy and lymphoma/myeloma at MD Anderson.

The event was a who’s who of Houston-based cancer specialists. Speakers included our city’s favorite Nobel laureate, Jim Allison, director of the James P. Allison Institute, as well as MD Anderson’s vice president of research, Eyal Gottlieb. Attendees were welcomed by the leaders of the initiative, Rice’s Gang Bao and MD Anderson’s Jeffrey Molldrem.

“This collaborative initiative builds on the strong foundation of our existing relationship, combining Rice’s expertise in bioengineering, artificial intelligence and nanotechnology with MD Anderson’s unmatched insights in cancer care and research,” Rice’s president Reginald DesRoches says at the event. “This is a momentous occasion to advance cancer research and treatment with the innovative fusion of engineering and medicine.”

The collaboration is part of Rice’s 10-year strategic plan for leadership in health innovation, called “Momentous: Personalized Scale for Global Impact.” Its goals include a commitment to responsible use of cutting-edge AI.

“As both institutions continue to make breakthroughs every day, we hope this collaborative will enable us to tackle the complex challenges of cancer care and treatment more effectively, ultimately improving the lives of patients here in Houston and beyond," Carin Hagberg, senior vice president and chief academic officer at MD Anderson, adds. "Whether our researchers are working on the South Campus or within the hedges of Rice, this collaborative will strengthen each other’s efforts and push the boundaries of what is possible in cancer.”

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

Cancer-fighting Houston lab led by Nobel laureate receives $5M grant at annual event

supporting research

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

Allison, who won the Nobel Prize in 2018, leads his namesake institute that was founded in 2022 to advance translational and clinical within cancer to create new, synergetic therapies. In addition to his role as director of the institute, he is regental professor and chair of Immunology at MD Anderson.

At the symposium, Jack and Judi Johnson presented a $5 million gift to the Allison Institute on behalf of the David and Eula Wintermann Foundation, a private organization dedicated to funding the advancement of medical education and research. A longtime supporter of MD Anderson, the foundation’s donation will go towards recruitment and technology for the institute, as well help fund clinical trials.

The money will help support several researchers, who will be known as Wintermann Scholars. The chosen great minds run the gamut from early career scientists to world-renowned experts in fields including immunotherapy, genetics, cancer biology, data science, bioinformatics, spatial profiling or the microbiome.

It was clear to us that the work happening within the Allison Institute has the potential to transform the lives of so many patients,” said Johnson, president of the Wintermann Foundation. “Our hope is that, with our support, we can help close the distance from the lab to the clinic so the incredible advancements underway can sooner help more cancer patients and their families.”

But the attendees on Oct. 10 learned far more than that. They were treated to a conversation between Allison and Carolyn Bertozzi, also a Nobel laureate, moderated by Alice Park, a senior health correspondent at Time. Park also took part in a fireside chat with Allison institute leaders, joined by MD Anderson President Peter WT Pisters and Chief Scientific Officer Giulio Draetta. Additional sessions also included presentations from big names like Mark Dawson, Elizabeth Jaffee, and Philip Greenberg.

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” said Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.”

The University of Texas MD Anderson Cancer Center was recognized for advancements in electronic functionality, AI and robotics. Photo via mdanderson.org

Houston hospital named among smartest in the nation

hi, tech

Houston hospitals are chock-full of smart people. But they’re also equipped with lots of “smart” technology. In fact, five local hospitals appear on Newsweek’s new list of the world’s best “smart” hospitals.

To compile the list, Newsweek teamed up with data provider Statista to rank the world’s top 330 hospitals for the use of smart technology. The ranking factors were electronic functionality, telemedicine, digital imaging, artificial intelligence (AI), and robotics.

The highest-ranked Houston hospital is the University of Texas MD Anderson Cancer Center, appearing at No. 6. The hospital was recognized for advancements in electronic functionality, AI and robotics.

“MD Anderson has a significant opportunity and a responsibility to our many stakeholders to create a digital ecosystem that promotes collaboration and advances scientific discovery to enhance patient outcomes,” David Jaffray, the cancer center’s chief technology and digital officer, said in a 2021 news release.

“Through our ongoing focus on enabling the use of new technologies to place quantitative data in context for our researchers,” Jaffray added, “we foster cutting-edge oncology data science to inform our cancer discovery research and to accelerate translation of our research findings into benefits for cancer patients.”

Ahead of MD Anderson on the list are:

  1. Mayo Clinic in Rochester, Minnesota.
  2. Cleveland Clinic in Cleveland.
  3. Massachusetts General Hospital in Boston.
  4. Johns Hopkins Hospital in Baltimore.
  5. Mount Sinai Hospital in New York City.

Other Houston hospitals on the list are:

  • Houston Methodist Hospital, No. 11.
  • Baylor St. Luke’s Medical Center, No. 105.
  • Texas Children’s Hospital, No. 197.
  • Memorial Hermann-Texas Medical Center, No. 266.
Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

AccessPath is a novel, affordable, slide-free pathology system that helps surgeons determine if they have completely removed tumors during surgery. Photo via Getty Images

Promising Houston cancer research project wins $18M grant

fresh funding

The Biden-Harris administration is deploying $150 million as a part of its Cancer Moonshot initiative, and a research team led by Rice University is getting a slice of that pie.

AccessPath is a novel, affordable, slide-free pathology system that helps surgeons determine if they have completely removed tumors during surgery. Rebecca Richards-Kortum, a Rice bioengineering professor and director of the Rice360 Institute for Global Health Technologies, is the lead PI on the project that is receiving up to $18 million over five years from the Advanced Research Projects Agency for Health (ARPA-H).

“Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Richards-Kortum says in a news release.

The project is focused on two types of cancer, breast and head and neck cancer, and Ashok Veeraraghavan, chair of Rice’s Department of Electrical and Computer Engineering and a professor of electrical and computer engineering and computer science, is a co-PI and Tomasz Tkaczyk, a professor of bioengineering and electrical and computer engineering at Rice, is also a collaborator on the project.

AccessPath is addressing the challenge surgeons face of identifying the margin where tumor tissue ends and health tissue begins when removing tumors. The project not only hopes to provide a more exact solution but do so in an affordable way.

“Precise margin assessment is key to the oncologic success of any cancer operation,” adds Dr. Ana Paula Refinetti, an associate professor in the Department of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center and one of the lead surgeons PIs on the project. “The development of a new low-cost technology that enables immediate margin assessment could transform the landscape of surgical oncology — particularly in low-resource settings, reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes.”

The project optimizing margin identification with a fast-acting, high-resolution microscope, effective fluorescent stains for dying tumor margins, and artificial intelligence algorithms.

AccessPath is a collaboration between Rice and MD Anderson Cancer Center, other awardees in the grant include the University of Texas Health School of Dentistry, Duke University, Carnegie Mellon University and 3rd Stone Design.

“AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” Ramamoorthy Ramesh, Rice’s executive vice president for research, says in the release. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center. I am thrilled for Rebecca and her team; it’s teamwork that makes discoveries like these possible.”

Rebecca Richards-Kortum, a Rice bioengineering professor and director of the Rice360 Institute for Global Health Technologies, is the lead PI on the project. Photo by Jeff Fitlow/Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston e-commerce platform expands logistics network with acquisition of fulfillment operations arm

M&A move

A Houston e-commerce unicorn has made its latest strategic acquisition.

Cart.com, which operates a multichannel commerce platform, announced that it has acquired Guthy-Renker's wholly-owned fulfillment operations arm OceanX. The terms of the deal were not disclosed. Around 200 OceanX employees will be assumed onto the Cart.com team, and the fast-growing company will add two new facilities totaling over 600,000 square feet to its network, expanding to include a West Coast distribution hub in Southern California and its third facility near Columbus, Ohio.

"Acquiring OceanX is part of Cart.com’s strategy to continue to scale our platform and capabilities across industries, leveraging our proprietary technology to improve efficiency and deliver superior results to our clients and their customers,” Omair Tariq, Cart.com founder and CEO, says in a news release. “By deploying our Constellation OMS and WMS software and seasoned operations team across these two new facilities, we will improve order visibility, labor efficiency, shipping costs and customer satisfaction for the benefit of our new clients.”

Cart.com now has 17 omnichannel fulfillment and distribution centers with around 10 million square feet and more than 1,600 team members, according to the company.

With the transition, Guthy-Renker's Co-Founder and Co-Chairman Bill Guthy will serve as a strategic adviser to Cart.com.

The move broadens Cart.com's presence in the high-volume beauty, wellness, and lifestyle industries, and the company now will work with supply chains from numerous brands, including Meaningful Beauty, The Body Firm, Smileactives, and Westmore Beauty.

“Cart.com has built a comprehensive, enterprise-grade logistics network with modern, digital capabilities that offer unparalleled visibility, control and efficiency for our brands,” Rick Odum, CEO of Guthy-Renker, says in the release. “This partnership will marry our own channel and marketing expertise with their track record of driving growth and savings for high-volume, high-SKU brands, supercharging performance across our portfolio.”

Earlier this year Cart.com secured $105 million in debt refinancing from investment manager BlackRock and a $25 million series C extension round.

In April, the company acquired an Amazon partner, Ohio-based Amify, a company that provides optimization and advertising solutions

10 years in: Houston entrepreneur reflects on lessons learned

guest column

Just as the job market is soaring, so is the state of entrepreneurship in America. And increasingly, people are launching their businesses in Houston.

As InnovationMap reported, our city is a top startup ecosystem, now ranked among the top 50 in the world. One of the fastest-growing sectors is climate tech. According to a recent analysis, the global climate tech market is expected to reach a massive $162 billion by 2033.

All those big numbers boil down to individual, hardworking people with high hopes, big dreams, and a willingness to take risks. Maybe that includes you.

This month, my company reached a milestone. We’ve been around for a decade, which means we’ve beaten the odds. An estimated two-thirds of businesses fail within 10 years. This has been nothing short of a chaotic, exhilarating, and sometimes unforgiving journey. I've been blessed and cursed, from hurricanes to a pandemic, losing my vision to filming documentaries, serving in the US Department of Energy during two administrations to an epic ringing of the closing bell on Wall Street. The successes have been sweet, but the lessons learned are the real treasure.

Here are my five biggest takeaways from a decade in the trenches of entrepreneurship.

Master your market

A deep understanding of the market is crucial to achieve success. By delving into the intricacies of how it operates, identifying gaps you can fill, and engaging with individuals and companies eager to see those gaps addressed, you lay the foundation for a viable and impactful venture. Building credibility and establishing a network over the long term opens doors. I experienced this firsthand in the oil and gas, where my market knowledge and 15 years of experience allowed me to create a business that champions the energy workforce of the future.

However, markets are constantly evolving, and even more so today than ever. It’s hard to bring things to market, so master the market, and listen to the voice of the customer to stay ahead.

Takeaway:

Embrace the power of market mastery and credibility to pave the path to success.

Grit is everything

When I think of resilience, one image stands out—the "man in the arena." (Or I should say the woman!). It's a metaphor often cited, and for good reason. What are you even doing if you're not stepping into the ring, getting your hands dirty, and taking the punches? Grit is what keeps you moving when the odds are against you. Change is inevitable; challenges will come. But grit? That’s what pushes you to stand back up and keep going. If you’re an entrepreneur, there’s no room for half-hearted effort. You're either in the ring or watching from the sidelines.

Takeaway:

The ability to endure setbacks and adapt separates those who thrive from those who fold.

You need more than you think

A hard truth I’ve learned the painful way. When I first started Pink Petro, a mentor of mine and now very successful entrepreneur turned investor told me to “Don’t take capital until you need it.” His advice helped me keep a large percentage of ownership in my company, however I learned that you will always need more time, money, and resources than anticipated. As a solo founder, it is easy to underestimate the financial and emotional cost of building something from scratch, alone. Whether it’s product development, marketing, an acquisition or hiring top talent, it all takes capital.

Takeaway:

Plan. Then, double that plan. Odds are, you’ll need it.

Ask without fear

Whether seeking investment, resources or support, learning to ask for what you need is a game-changer. This one didn’t come naturally to me—I had to lean in and push past the stubbornness of “never needing anyone’s help”. Here’s the truth: most people are afraid to ask. But asking is often what gets you one step closer to your goals. Whether it’s a pitch to an investor or a favor from a mentor, the worst someone can say is “no.” And in business, a "no" is just a chance to refine your pitch for the next opportunity.

Takeaway:

Advocating for your needs isn’t selfish—it’s essential.

The sharks are in the water

Building something meaningful attracts all kinds of attention. Over the years, I’ve dealt with doubters, copycats, and even former allies. At first, it stung. But then I realized something important -- sharks will always show up if you’re making waves. It’s a sign you’re on the right path. The key is to stay focused on your vision and not get distracted

by the noise.

Takeaway:

If you have skeptics and imitators, take it as validation that what you’re doing matters.

Bonus lesson: Put your mask on

This one is personal. Here’s the thing—if you’re running on empty, you’re no good to your business, team, or yourself. That’s when I learned the importance of self-care. It’s not selfish—it’s survival.

Takeaway:

Take care of yourself first. Your business depends on it.

Looking back, ten years feels like a lifetime. The truth is that entrepreneurship is hard. It requires grit, humility, persistence, and the courage to rise above challenges. But it’s also one of the most rewarding ventures you can take on.

If you’re out there building something, keep going. Step into the ring. Learn from every fall. Trust yourself, and never stop moving forward—you might surprise yourself with how far you can go.

------

Katie Mehnert is founder and CEO of ALLY Energy, formerly Pink Petro and serves on the National Petroleum Council.

Here are the most-read energy tech stories of the year

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. As the energy capital of the world, Houston has its fair share of energy tech stories that trended among readers. Be sure to click through to read the full story.

Houston accelerator names inaugural cohort to propel digital transformation in energy

The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. Photo via Getty Images

Houston-based Venture Builder VC has kicked off its NOV Supernova Accelerator and named its inaugural cohort.

The program, originally announced earlier this year, focuses on accelerating digital transformation solutions for NOV Inc.'s operations in the upstream oil and gas industry. It will support high-potential startups in driving digital transformation within the energy sector, specifically upstream oil and gas, and last five months and culminate in a demo day where founders will present solutions to industry leaders, potential investors, NOV executives, and other stakeholders.

The NOV Supernova Accelerator will work to cultivate relationships between startups and NOV. They will offer specific companies access to NOV’s corporate R&D teams and business units to test their solutions in an effort to potentially develop long-term partnerships. Read more.

Promising Houston startup expands energy efficiency product to Middle East, Singapore

NanoTech is targeting new overseas markets for its energy efficiency products. Photo via Getty Images

NanoTech Materials has announced a big expansion for its business.

The Houston company, which created a roof coating using nanotechnology that optimizes energy efficiency, has partnered with Terminal Subsea Solutions Marine Service SP to bring its products to the Gulf Cooperation Council and Singapore. TSSM will become a partner of Houston’s NanoTech Materials products, which will include the Cool Roof Coat, Vehicular Coat, and Insulative Coat for the GCC countries and Singapore.

NanoTech Materials technology that ranges from roof coatings on mid- to low-rise buildings to shipping container insulation to coating trucks and transportation vehicles will be utilized by TSSM in the partnership. NanoTech’s efforts are focused on heat mitigation that can reduce energy costs, enhance worker safety, and minimize business risks in the process. Read more.

Rice University launches $12.5M climate tech accelerator

Rice University announced a new climate tech initiative backed by Woodside Energy. Photo by Natalie Harms/InnovationMap

Rice University has announced its latest initiative to advance clean energy technology into commercialization with a new partnership with a global energy company.

Woodside Energy, headquartered in Australia with its global operations in Houston following its 2022 acquisition of BHP Group, has committed $12.5 million over the next five years to create the Woodside Rice Decarbonization Accelerator.

"The goal of the accelerator is to fast track the commercialization of innovative decarbonization technologies created in Rice labs," Rice University President Reginald DesRoches says to a crowd at the Ion at the initiative's announcement. "These technologies have the potential to make better batteries, transitistors, and other critical materials for energy technologies. In addition, the accelerator will work on manufacturing these high-value products from captured and converted carbon dioxide and methane." Read more.

10 most-promising energy tech startups named at annual Houston event

Over 500 people attended the 21st annual Energy Tech Venture Forum hosted by the Rice Alliance. Photo courtesy of Rice

Investors from around the world again identified the most-promising energy tech startups at the Rice Alliance for Technology and Entrepreneurship's annual event.

"The recognition that Houston is the epicenter of energy transition is growing. It's something we are championing as much as possible so that the world can know exactly what we're doing," Paul Cherukuri, chief innovation officer at Rice University says at the 21st annual Energy Tech Venture Forum.

The event took place during the inaugural Houston Energy and Climate Startup Week, and nearly 100 startups from 23 states and seven countries pitched investors Wednesday, September 11, and Thursday, September 12. At the conclusion of the event, the investors decided on 10 companies deemed "most promising" from the presentations. Read more.

Port Houston lands $3M EPA grant to drive green initiatives, cleantech innovation

The grant, funded by the federal Inflation Reduction Act, will help promote cleaner air, reduced emissions, and green jobs. Photo via Getty Images

Port Houston’s PORT SHIFT program is receiving nearly $3 million from the U.S. Environmental Protection Agency’s Clean Ports Program.

The grant, funded by the federal Inflation Reduction Act, will help promote cleaner air, reduced emissions, and green jobs.

“With its ambitious PORT SHIFT program, Houston is taking a bold step toward a cleaner, more sustainable future, and I’m proud to have helped make this possible by voting for the Inflation Reduction Act,” U.S. Rep. Sylvia Garcia says in a news release. Read more.